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Objective: Contact between blood and the synthetic surfaces of a cardiopulmonary
bypass circuit leads to platelet activation, and resultant platelet dysfunction con-
tributes to postoperative bleeding. We compared the effects of various platelet
inhibitors on preservation of platelet function during simulated cardiopulmonary
bypass circulation.
Methods: Fresh human blood was recirculated in an in vitro cardiopulmonary
bypass model circuit. We measured various platelet activation markers including
expressions of PAC-1 and P-selectin, annexin V binding, and microparticle forma-
tions by means of whole-blood flow cytometry.
Results: Two types of glycoprotein IIb/IIIa complex antagonists, peptide-mimetic
FK633 and abciximab and prostaglandin E1, significantly prevented platelet loss and
the increase in binding of PAC-1, an antibody specific for fibrinogen receptor on
activated platelets, during extracorporeal circulation of heparinized blood. These
antagonists significantly suppressed but did not abolish P-selectin expression, an-
nexin V binding, and microparticle formation. Anti–von Willebrand factor mono-
clonal antibody and aurin tricarboxylic acid (an inhibitor of glycoprotein Ib) had no
effect on platelet activation during simulated cardiopulmonary bypass circulation.
These data suggest that inhibition of fibrinogen binding glycoprotein IIb/IIIa com-
plex is partly effective in attenuating platelet activation in a heparinized cardiopul-
monary bypass model circuit. The direct thrombin inhibitor argatroban prevented
platelet loss and expression of P-selectin significantly more than did heparin. A
combination of FK633 with argatroban as a substitute for heparin further prevented
platelet loss and platelet secretion during simulated cardiopulmonary bypass circu-
lation, although the inhibition of microparticle formation was less.
Conclusion: The inhibition of both platelet adhesion and thrombin may be effective
to preserve platelet number and function during cardiopulmonary bypass circula-
tion.
Platelet consumption and dysfunction during cardiopulmonary bypass(CPB) result from contact activation with synthetic surfaces of CPBcircuits and the shear stress of the flowing blood.1-3 The bleedingtendency during and after cardiac operations with CPB is largelycaused by platelet dysfunction.4 Platelet dysfunction has been repro-duced in vitro in recirculating heparinized human blood in a CPB
model circuit composed of a tube and reservoir with a roller-head pump.1,5 We have
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shown that the heparin-coated circuit maintains platelet
aggregability in the in vitro extracorporeal circulation.5
Temporary pharmacologic inhibition of platelets (platelet
anesthesia6) during CPB is another potential strategy for
preserving platelet number and function. We tested the
effects on platelet consumption and functions during in vitro
heparinized CPB circulation of various platelet inhibitors,
including FK633 (a peptide-mimetic glycoprotein [Gp] IIb/
IIIa complex antagonist),7 abciximab (Fab fragment of an-
tibody against GpIIb/IIIa complex),8,9 an anti–von Wille-
brand factor (vWF) monoclonal antibody (AJvW-2),10 aurin
tricarboxylic acid (ATA, an inhibitor of platelet GpIb),11,12
and prostaglandin E1 (PGE1). To assess platelet activation
during blood–synthetic surface contact, we quantitated
platelet functional and structural alterations during a simu-
lated CPB circulation with heparin used as an anticoagulant
by means of whole-blood flow cytometry.
Platelets can be activated not only by contact activation
with an in vitro CPB model circuit but also by coming in
contact with thrombin, produced as a terminal event in
coagulation cascades.5 Anticoagulation with heparin during
CPB circulation does not entirely prevent surface-induced
coagulation and the adherence of blood cells to membranes,
even though heparin is the anticoagulant generally used in
extracorporeal circulations (hemodialysis and CPB). The
use of heparin can lead to other complications, including
platelet dysfunction, thrombocytopenia, and lipid abnormal-
ities, all predisposing toward cardiovascular disorders.13
Argatroban, a small-molecule synthetic direct thrombin in-
hibitor, binds rapidly and reversibly to both clot-bound and
soluble thrombin.14 Because the utility of combining a
direct thrombin inhibitor and a GpIIb/IIIa complex inhibitor
has not been fully explored, we wanted to determine the
efficacy of combining argatroban and FK633 to enhance
inhibition of platelet activation during simulated extracor-
poreal circulation.
Material and Methods
Reagents
FK633, N-[4-(4-amidinophenoxy)butyryl]-a-L-aspartyl-L-valine,
was provided by Fujisawa Pharmaceutical (Fujisawa Pharmaceu-
tical Co, Ltd, Osaka, Japan), abciximab (Reopro) was purchased
from Eli Lilly (Eli Lilly and Company, Indianapolis, Ind), and
PGE1 was provided by Ono Pharmaceutical (Ono Pharmaceutical
Co, Osaka, Japan). AJvW-2 was provided by Ajinomoto Pharma-
ceutical (Ajinomoto Pharmaceutical Co, Tokyo, Japan). ATA was
purchased from Sigma (Sigma, St Louis, Mo), and low–molecular
weight ATA polymers (molecular weight5 kd) were collected at
4°C with a 5-kd cutoff filter (Ultrafree-4; Millipore Corporation,
Bedford, Mass). Argatroban was provided by Mitsubishi Pharma
(Mitsubishi Pharma Co, Osaka, Japan).
Preparation of the Model of CPB
The model circuits (surface area 0.01 m2) were assembled from
standard medical-grade polyvinylchloride tubing (diameter 3.0
mm) with polycarbonate connectors and reservoirs.5 These model
circuits did not connect with oxygenators or air filters. Blood was
drawn by venipuncture without stasis from informed volunteer
staff members with a 17-gauge needle or taken into an ethylenedia-
minetetraacetic acid–treated tube for full blood count. Blood sam-
ples were diluted to approximate bypass hematocrit (25%) with
priming solution (Veen D; Nikkenkagaku, Tokyo, Japan). Heparin
chloride was injected in a standard heparin dose used in clinical
CPB (3 U/mL). In each experimental study (n  5), FK633 (100
and 500 nmol/L), abciximab (2 and 10 g/mL), ATA (200 mg/
L), or AJvW-2 (3.0 g/mL) was added to the reservoir just
before circulation. In some experiments with 500-nmol/L FK633
(n  5), argatroban (3 g/mL) was added to the circuit reservoir
as a substitute for heparin. The blood priming solution was recir-
culated by a precisely shimmed, barely occlusive calibrated roller
pump (Senko Medical Co, Ltd, Osaka, Japan) for 3 hours at a rate
of equal to twice the circulating volume per minute (100 mL/min).
Blood temperature was maintained at approximately 28°C. Shear
stress () was calculated as follows:   4Q/r3, where  is
viscosity, Q is blood flow, and r is tube radius. Shear stress in the
model circuit was approximately 30 dyne/cm2.
Blood Sampling and Platelet Preparation
Samples were taken at six times: (1) before circulation; (2) 5
minutes, (3) 60 minutes, (4) 120 minutes, and (5) 180 minutes after
beginning circulation; and (6) 120 minutes after the completion of
circulation. Whole blood samples were separated into two parts;
one mixed with ethylenediaminetetraacetic acid was analyzed for
platelet counting with Sysmex KX-21 (Sysmex Co, Kobe, Japan),
whereas the other was immediately mixed with 1 volume of 3.8%
sodium citrate solution to 9 volumes of whole blood for flow
cytometry.
Flow Cytometry of Activated Platelets and Platelet-
Derived Microparticles
We detected activated platelets in whole blood with a modification
of the whole-blood flow cytometry method,15-17 as described in
detail here. The following monoclonal antibodies were used for
this study: SZ2 (Immnotech, Marseilles, France), which reacts
with the vWF-binding site of the -chain of GpIb; SZ22 (Immno-
tech), which reacts with GpIIb; CLB-Thromb/6 (Immnotech),
which reacts with P-selectin of -granule membrane; and PAC-1
(BD Biosciences, San Jose, Calif), which reacts with activated
fibrinogen receptor GpIIb/IIIa complex.15 Increased expression of
P-selectin is indicative of -granule secretion. Whole blood con-
taining platelets (about 1.0  106) was incubated with 10 L
fluorescein isothiocyanate–conjugated (FITC) antibody for 30
minutes at room temperature and in the dark. Samples were fixed
in 1% paraformaldehyde (pH 7.3) at 4°C and analyzed with an
Ortho Cytron Absolute flow cytometer (Ortho Diagnostic Systems,
Tokyo, Japan). For each sample a gate was drawn around the
platelet population, and the fluorescence signal from 10,000 indi-
vidual cells was measured with the gain setting in logarithmic
mode. When measuring GpIIb and GpIb, which were strongly
expressed on all platelets at all times, the data were expressed as
mean fluorescence intensity. The “flip-flop” of the platelet mem-
brane, leading to the exposure of negatively charged phospholipids
(predominantly phosphatidylserine) in platelet activation, was
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studied with FITC annexin V.18,19 Annexin V binding is indicative
of phosphatidylserine exposure, which results in platelets with an
increased procoagulant tendency. Platelets were incubated with
FITC annexin V (BD PharMingen, San Diego, Calif) for 15
minutes at room temperature in the dark with calcium-containing
annexin V–binding buffer (10-mmol/L N-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid and sodium hydroxide, pH7.4, 140-
mmol/L sodium chloride, 2.5-mmol/L calcium chloride) and ana-
lyzed with an Ortho Cytron Absolute. When measuring P-selectin,
PAC-1, and annexin V, which were present at low levels on
unstimulated platelets and appear at significant levels on activa-
tion, the data were expressed as the percentage of fluorescence-
positive platelets.
Platelet-derived microparticles (PMPs) were detected with a
modification of a documented method.20 Whole blood was incu-
bated with 10 L SZ22 (platelet identifier monoclonal antibody)
for 30 minutes at room temperature in the dark. Only particles
positive for GpIIb were gated, to distinguish PMPs from electronic
noise. A sample of 10,000 FITC-positive particles in the PMP gate
was then counted to determine the number of PMPs released per
10,000 platelets.
Statistical Analysis
StatView 5.0 (SAS Institute, Inc, Cary, NC) was used for statistical
analysis. All data are given as mean  SD. Differences at each
sampling of data between the two groups were assessed with the
Student t test. Comparisons between groups were made with
2-factor repeated measures analysis of variance. When the analysis
of variance indicated a significant effect, the differences between
the two groups were evaluated with the Student t test. The Pearson
correlation coefficient was determined for the analysis of the
relationship between platelet number and each platelet activation
marker.
Results
Prevention of Platelet Function During in Vitro
Extracorporeal Circulation by Various Platelet
Inhibitors
When heparinized blood was recirculated with vehicle only
(control, n  5), platelet counts (initial count 10.98  1.80
 104 cells/L) gradually fell to 58.2%  6.2% of the
initial level at 180 minutes, as shown in Figure 1 and Table
Figure 1. Effects of FK633, abciximab, and PGE1 on platelet counts; expressions of platelet surface GpIb, PAC-1,
P-selectin, and annexin V; and PMP formation during simulated CPB circulation. Heparinized (3 U/mL) blood was
recirculated with vehicle (control, filled circles) or with 500-nmol/L FK633 (filled triangles), 2-g/mL abciximab
(open squares), or 50-ng/mL PGE1 (open circles). Data points represent mean; error bars represent SD (n  5). Plus
signs indicate P < .05, asterisks indicate P < .01, and double asterisks indicate P < .001.
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1. These results were similar to those reported previously
for recirculated blood without platelet inhibitors.1,2 There
was no significant change in the platelet surface expression
of GpIIb throughout the circulation (Table 1). The percent-
age of PAC-1 (activated GpIIb/IIIa complex)–positive
platelets increased from 4.6%  1.2% before circulation to
8.6%  3.1% after 5 minutes of extracorporeal circulation
in the control circuits and reached the peak (27.1% 5.9%)
after 180 minutes of circulation. The percentage of annexin
V–positive platelets (surface expression of phosphatidylser-
ine) increased from 3.5% 0.8% at initial level to 36.6%
4.1% after 180 minutes of circulation in the control group
(Table 1). The expression of surface GpIb (mean fluores-
cence intensity) in the control group (148.9  2.9 at the
initial level) decreased significantly during circulation,
reaching the lowest level (130.2 3.8) after 180 minutes of
extracorporeal circulation, as reported previously else-
where.6 The expression (percentage of positive platelets) of
platelet surface P-selectin (the integral membrane protein of
-granule) increased from 4.0%  0.7% before circulation
to 8.9%  0.9% after 5 minutes of extracorporeal circula-
tion and reached the peak (14.6%  1.9%) after 180 min-
utes of circulation. During extracorporeal circulation the
release of PMPs was increased from 227  81 per 104
platelets before circulation to 1241  250 per 104 platelets
after 180 minutes of circulation.
GpIIb/IIIa complex antagonists FK633 (500 nmol/L) and
abciximab (10 g/mL) significantly inhibited the decrease
in platelet counts induced by in vitro CPB circulation (Fig-
ure 1). These inhibitors dose dependently prevented platelet
loss during heparinized CPB circulation (Table 1). PGE1 at
50 ng/mL also had a protective effect on platelet number,
but the protective effect of PGE1 was less. Abciximab,
FK633, and PGE1 blocked increases in PAC-1–positive
platelets, annexin V binding, expression of P-selectin, and
PMP formation during simulated CPB circulation (Figure 1
and Table 1). Among these drugs, abciximab appeared to be
the most effective. Although abciximab completely blocked
platelet loss and the increase in PAC-1–positive platelets,
the antibody only attenuated expression of other functional
markers such as P-selectin, annexin V binding, and PMP
formation. We then analyzed the relationship between plate-
let counts and functional markers of platelet activation. The
correlation coefficients between platelet number and expres-
sions of PAC-1, annexin V, GpIb, P-selectin, and PMP
generation were 0.622 (P  .0001), 0.527 (P  .0001),
0.476 (P  .0002), 0.557 (P  .0001) and 0.477(P 
.0001), respectively. Figure 2 shows data on the negative
TABLE 1. Dose-dependent effects of FK633, abciximab, and PGE1 on platelet activation during in vitro extracorporeal
circulation
Control
FK633 Abciximab PGE1
100 nmol/L 500 nmol/L 2 g/mL 10 g/mL 50 ng/mL 100 ng/mL
Platelet counts (104 cells/mm3)
Before 11.0 1.8 10.3 0.9 10.2 1.1 10.3 2.0 10.7 2.1 11.7 1.3 11.9 1.6
180 min 6.3 1.0 7.7 1.0* 8.6 0.8† 9.5 1.9‡ 10.1 2.2‡ 7.9 0.6* 9.0 0.7‡
GpIb (mean fluorescence intensity)
Before 148.9 2.9 149.9 3.6 149.5 3.7 148.8 2.6 148.9 2.0 148.0 2.9 148.2 2.9
180 min 130.2 3.8 130.4 3.2 135.3 4.5* 134.7 3.1* 135.8 4.0* 132.3 5.9 137.4 5.1*
GpIIb (mean fluorescence intensity)
Before 168.0 4.2 165.4 3.2 168.3 2.9 169.0 2.7 169.6 0.8 167.7 2.9 167.3 2.9
180 min 161.6 1.5 161.8 4.6 162.8 2.0 164.1 2.0 165.2 1.7 160.0 5.0 161.2 2.5
PAC-1 (% positive platelets)
Before 4.6 1.2 4.7 0.8 4.5 1.5 1.2 0.2 1.2 0.4 3.5 1.5 3.3 1.4
180 min 27.1 5.9 26.4 7.5 8.7 2.0‡ 1.5 0.7‡ 1.6 0.4‡ 13.1 4.0† 6.8 2.8‡
P-selectin (% positive platelets)
Before 4.0 0.7 4.6 1.5 4.7 1.5 3.6 1.0 3.5 1.3 4.5 0.3 4.3 0.3
180 min 14.6 1.9 11.4 2.8† 11.7 2.5† 9.9 1.6‡ 9.5 2.5‡ 11.3 2.6† 8.1 1.4‡
Annexin V (% positive platelets)
Before 3.5 0.8 3.6 1.3 3.6 1.0 2.3 1.0 2.3 1.0 5.4 2.4 5.1 1.7
180 min 36.6 4.1 16.8 4.3† 14.1 4.5† 19.1 4.6† 14.5 5.7† 21.0 7.3* 9.4 1.9‡
PMPs (per 104 platelets)
Before 227 81 239 38 221 38 180 38 199 45 245 84 233 56
180 min 1241 250 1136 358 928 182* 737 227† 466 217† 940 393* 692 167†
Platelet counts; platelet surface expressions of GpIb, GpIIb, PAC-1, P-selectin, and annexin V, and PMP counts in the control group and groups with
antiplatelet drugs FK633 (100 and 500 nmol/L), abciximab (2 and 10 g/mL), and PGE1 (50 and 100 ng/mL) before in vitro extracorporeal circulation and 180
minutes afterward. All data are shown as mean  SD (n  5).
*P  .05 between the control group and the group given antiplatelet drugs.
†P  .01 between the control group and the group given antiplatelet drugs.
‡P  .001 between the control group and the group given antiplatelet drugs.
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correlation between platelet numbers and expressions of
PAC-1 and P-selectin. PAC-1 expression was most strongly
correlated with the decrease in platelet count during simu-
lated CPB circulation.
An anti–human vWF monoclonal antibody, AJvW-2,
and a polymeric anionic aromatic compound, ATA, both of
which inhibit vWF binding to platelet GpIb, did not prevent
the decrease in thrombocyte counts during simulated CPB
circulation, as shown in Figure 3. These inhibitors did not
inhibit increases in PAC-1 expression, annexin V binding,
P-selectin expression, and PMP formation during in vitro
extracorporeal circulation.
Combined Effects of Argatroban and FK633 on
Platelet Activation During Extracorporeal Circulation
Because thrombin is formed and circulates during heparin-
ized extracorporeal circulation,5 platelets probably are acti-
vated even though aggregation and adhesion are inhibited.
Argatroban, a small-molecule synthetic direct thrombin in-
hibitor, binds rapidly and reversibly to both clot-bound and
soluble thrombin.14 The relatively short elimination half-life
of argatroban (40-50 minutes) and its reversible binding
allow rapid achievement of therapeutic effects on initiation
of therapy and rapid restoration of normal hemostasis on
cessation of therapy. We tested argatroban in an in vitro
extracorporeal circulation as a substitute for heparin.
As shown in Figure 4, argatroban alone better maintained
the platelet number, and there was a lesser degree of in-
crease in the expression of P-selectin than seen with heparin
alone. In the group treated with FK-633 and argatroban,
platelet counts at 180 minutes were significantly higher than
those in the group given FK-633 and heparin. In the group
given FK-633 and argatroban, expressions of PAC-1 and
P-selectin at 180 minutes of extracorporeal circulation were
also significantly more inhibited than seen in the group
given FK-633 and heparin. However, there were no signif-
icant differences in annexin V binding and PMP formation
between these two groups.
Discussion
Our study indicates that the decrease in platelet number was
most strongly correlated with increase in the expression of
PAC-1 during extracorporeal circulation with heparin, al-
though other platelet activation markers tested also had
negative correlations with platelet number. Gradual platelet
consumption is thought to be the result of platelet adhesion
and activation to foreign surfaces in the extracorporeal
circuits,2 partly mediated by interaction of platelet GpIIb/
IIIa complex receptors and fibrinogen bound to the surfaces
of bypass tubing.21 It seems reasonable to assume that the
direct inhibition of interaction between active GpIIb/IIIa
complex receptor and fibrinogen effectively contributes to
preservation of platelet counts in CPB circulation. GpIIb/
IIIa complex antagonists abciximab and FK633 prevented
platelet loss almost completely during simulated CPB cir-
culation, whereas these drugs only attenuated platelet acti-
vation, as indicated by the expression of P-selectin (-
granule secretion) and annexin V binding (procoagulant
activity). Although PGE1 inhibited platelet activation and
preserved platelet function, the concentration of PGE1 was
higher than noted in clinical use.22 In addition, PGE1 is a
potent vasodilator that is rapidly metabolized in the pulmo-
nary circulation, and therefore its clinical use could be
limited.23 ATA, with a molecular mass of less than 5 kd,
inhibited vWF-mediated platelet aggregation.11 Borgdorff
and colleagues24 reported that ATA inhibited pump-induced
platelet aggregation and the loss of platelets in an extracor-
poreal circuit under shear stress, which was higher than in
our experimental condition. AJvW-2 (an anti-vWF mono-
clonal antibody) inhibited vWF binding to platelet GpIb by
ristocetin and blocked vWF-GpIb interaction under condi-
tions of a high shear rate.10 ATA and AJvW-2, inhibitors of
interaction between vWF and GpIb, had no protective effect
against platelet loss under our flow conditions with low
shear stress (approximately 30 dyne/cm2). Temporary and
reversible pharmacologic inhibition of platelet activation
may be needed during CPB to reduce postoperative bleed-
ing in cardiac surgery. Abciximab more effectively pre-
served platelet counts and function than did FK633 during
Figure 2. Correlation of platelet numbers and PAC-1 or P-selectin
expressions during simulated CPB circulation.
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extracorporeal circulation. Abciximab is a Fab fragment of
chimeric mouse/human immunoglobulin G antibody. Its
plasma half-life is 26 minutes, but the antiplatelet effect is
prolonged and irreversible after administration. Elimination
of abciximab from the human body in a clinical setting is
considerably slower; the catabolic beta half-life was esti-
mated to be 7 hours.8,9 Preoperative treatment with abcix-
imab does not increase surgical mortality, but exposure
before an operation has been reported to increase postoper-
ative bleeding and transfusion requirements and is associ-
ated with a higher incidence of mediastinal reentry.25 Cur-
rently it is impossible to neutralize the action of abciximab
at the end of extracorporeal circulation. Reversible GpIIb/
IIIa complex inhibitors tirofiban6 and eptifibatide26 have
shown to reduce platelet activation during CPB and to
decrease postoperative bleeding time in baboons. FK633 is
an arginine-glycine-aspartic acid peptide-mimetic GpIIb/
IIIa complex antagonist with a reversible antiplatelet effect
and its plasma half-life is 0.52 hours,7 which is shorter than
those of tirofiban and eptifibatide. Therefore a low–molecu-
lar weight GpIIb/IIIa complex antagonist such as FK633
may be a potential candidate for platelet protection during
CPB, although FK633, even at high doses, is less active
against platelet loss and PAC-1 expression during an in
vitro CPB circulation than is abciximab.
We have reported that the thrombin-antithrombin com-
plex, a marker of thrombin generation, increases progres-
sively and significantly during in vitro CPB circulation,
even if heparinized platelets are recirculated, and then de-
creases after termination of pumping.5 In addition to contact
activation of platelets, thrombin production may also con-
tribute to activating platelets during simulated CPB, the
result being increases in P-selectin expression, PAC-1 ex-
pression, and PMP formation. Heparin enhances platelet
aggregation induced by agonists such as adenosine diphos-
phate and epinephrine27,28 and shear stress–induced platelet
aggregation at both low and high shear stresses,29 whereas
heparin inhibits platelet reaction resulting from the action of
thrombin.30 Treatment with argatroban, a direct inhibitor of
thrombin with a short half-life, prevented platelet loss and
elevation of P-selectin more effectively than did heparin
during a simulated CPB circulation. There appeared to be no
Figure 3. Effects of AJvW-2 and ATA on platelet counts; expressions of platelet surface GpIb, PAC-1, P-selectin,
and annexin V; and PMP formation during simulated CPB circulation with heparin as anticoagulant. Heparinized
(3 U/mL) blood was recirculated with vehicle (control, circles), 200 g/mL ATA (diamonds), or 3.0 g/mL AJvW-2
(inverted triangles). Data points represent mean; error bars represent SD (n  5).
Kanemitsu et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 2 433
CS
P
significant differences as to annexin V binding and PMP
formation between these groups. The combination of ar-
gatroban and FK633 significantly inhibited platelet loss and
expressions of PAC-1 and P-selectin relative to findings
with heparin and FK633. Despite full inhibition of PAC-1
expression, the combination of both inhibitors only partially
prevented annexin V binding and PMP formation. Our
findings suggest that inhibition of both thrombin and plate-
lets is effective to preserve platelet number and function
during CPB circulation. For cardiac operations, prompt and
complete reversal of platelet inhibition is an absolute re-
quirement. The clinical disadvantage of argatroban is that
no neutralizing agent exists, such as protamine for heparin.
Therefore these combined therapies still may not be suffi-
cient to produce a meaningful decrease in postoperative
bleeding after cardiovascular operation. Definitive assess-
ments of efficacy and safety of combination of FK633 and
argatroban await in vitro and in vivo studies. It has become
increasingly evident that potent but reversible inhibition of
both of platelet aggregation and thrombin activity will be
needed if optimal extracorporeal circulation without platelet
loss is to be achieved.
We are grateful to Dr S. Nomura for advice on measuring PMP
formation by flow cytometry and to M. Ohara for critical com-
ments on the manuscript.
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